MedTrace Logo

Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis

NCT04769908 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-02-25

No results posted yet for this study

Summary

This study were designed to verify the better method of survival for ICC with distant metastasis. Since the traditional method for ICC with distant metastasis. was GEMOX(first-line treatment from NCCN guideline), our previous study found similar results from FOLFOX (second-line treatment from NCCN guideline) compared with GEMOX.

Our current study were conducted for further investigation to verify the better method for with distant metastasis.

Conditions

  • ICC

Interventions

DRUG

Systemic Chemotherapy

Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)

DRUG

Lenvatinib

Lenvatinib, 8mg or 12mg, po, QD

DRUG

Sintilimab

Sintilimab, IV, 200mg, q3w

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-23
Primary Completion
2021-12-01
Completion
2021-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04769908 on ClinicalTrials.gov